Patient adherence issues in the treatment of hepatitis C

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 763-773

  Larrey, Dominique ^a,b   Ripault, Marie Pierre ^a   Pageaux, Georges Philippe ^a  

^a HÔPITAL SAINT ELOI   (France)

^b IRB INSERM1040   (France)

Author keywords

Adherence to treatment; Hepatitis C; Quality of life; Therapeutic education

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN;

ANEMIA; ANTIVIRAL THERAPY; ASTHENIA; BODY WEIGHT DISORDER; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE QUESTIONNAIRE; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ERADICATION; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL DISEASE; HEPATITIS; HEPATITIS C; HEPATITIS QUALITY OF LIFE QUESTIONNAIRE; HUMAN; INFECTION; INFLUENZA; KIDNEY FAILURE; LIVER DISEASE QUALITY OF LIFE QUESTIONNAIRE; MEDICATION COMPLIANCE; NEUTROPENIA; NOTTINGHAM HEALTH PROFILE; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; QUALITY OF LIFE; RASH; REVIEW; SHORT FORM 36; SICKNESS IMPACT PROFILE; SKIN MANIFESTATION; SLEEP DISORDER; SOCIAL FUNCTIONING QUESTIONNAIRE; THROMBOCYTOPENIA; TREATMENT FAILURE; VIROLOGY;

EID: 84901467263     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S30339     Document Type: Review

References (80)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
3. Ghany MG, Strader DB, Thomas DL, Seef LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
4. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
6. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
7. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417-2428.
8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264.
9. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.
10. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in Genotype-1 infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
11. Larrey D. [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?]. Gastroenterol Clin Biol. 2002;26 Spec No 2:B283-B290. French.
12. Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009;30:14-27.
13. Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat. 2013;20:536-549.
14. Weiss JJ, Alcorn MC, Rabkin JG, Dieterich DT. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol. 2012;56:503-504.
15. Larrey D, Salse A, Ribard D, et al. Hepatitis C Network of Languedoc Roussillon (France). Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin. Clin Gastroenterol Hepatol. 2011;9:781-785.
16. Zanini B, Benini F, Pigozzi MG, et al. Addicts with chronic hepatitis C: difficult to reach, manage or treat? World J Gastroenterol. 2013;19:8011-8019.
17. Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who infect drugs requires overcoming barriers to care. World J Gastroenterol. 2013;19:7846-7851.
18. Russell M, Pauly MP, Moore CD, et al. The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. Drug Alcohol Depend. 2014;134:222-227.
19. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis. 2004;24:399-413.
20. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792-800.
21. Roudot-Thoraval F, Abergel A, Allaert F, et al. Groupe d'Etude Pour Hépavir. [Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences]. Gastroenterol Clin Biol. 2001;25:1061-1066. French.
22. Larrey D, Couzigou P, Denis J. [Chronic hepatitis C: management of side effects of treatment]. Gastroenterol Clin Biol. 2007;31:4S20-4S28. French.
23. Horsmans Y. Chronic hepatitis C, depression and interferon. J Hepatol. 2005;42:788-789.
24. Castera L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2006;24:1223-1230.
25. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-48.
26. Hézode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20 CUPIC)-NCT01514890. J Hepatol. 2013;59:434-441.
27. Constitution of the World Health Organization. In: Chronicle of the World Health Organization. Vol 1. Geneva: World Health Organization; 1947.
28. Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int. 2006;26:755-765.
29. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of Hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800.
30. Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;30:550-555.
31. Leplège A, Mesbah M, Marquis P. [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: the MOS SF-36 (version 1.1)]. Rev Epidemiol Sante Publique. 1995;43:371-379. French.
32. Davies GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther. 1994;16:334-343.
33. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57:946-952.
34. McHutchison JG, Ware JE Jr, Bayliss MS, et al; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34:140-147.
35. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multi-attribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996;34: 702-722.
36. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of disease specific questionnaire to measure heath related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
37. Gralnek IM, Hays RD, Kilbourne A, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease - the LDQOL 1.0. Am J Gastroenterol. 2000;95:3552-3565.
38. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res. 1998;7:39-55.
39. Remy AJ, Daurès JP, Tanguy G, et al. [Measurement of the quality of life in chronic hepatitis C: validation of a general index and specific index. First French results]. Gastroenterol Clin Biol. 1999;23:1296-1309. French.
40. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299-1301.
41. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol. 1999;31 Suppl 1:250-254.
42. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29:264-270.
43. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204-2212.
44. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433-439.
45. Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002;76: 10064-10068.
46. Häuser W, Zimmer C, Schiedermaier P, Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med. 2004;66:954-958.
47. Córdoba J, Flavià M, Jacas C, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003;39:231-238.
48. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol. 2001;32:413-417.
49. Piche T, Tran A. [Fatigue in patients with chronic hepatitis C: a sign to look for]. Gastroenterol Clin Biol. 2001;25:1059-1060. French.
50. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40:675-681.
51. Poynard T, Cacoub P, Ratziu V, et al; Multivirc group. Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002;9:295-303.
52. Berstein B, Kleinman J, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35: 704-708.
53. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
54. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17:1041-1045.
55. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
56. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J; VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003;6:566-573.
57. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54 Suppl 1:S57-S60.
58. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386.
59. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43-49.
60. Balfour L, Cooper C, Tasca GA, Kane M, Kowal J, Garber G. Evaluation of health care needs and patient satisfaction among hepatitis C patients treated at a hospital-based, viral hepatitis clinic. Can J Public Health. 2004;95:272-277.
61. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39:999-1007.
62. Organisation Mondiale de la Santé. Education Thérapeutique du Patient [Therapeutic Patient Education]. Geneva: World Health Organization; 1998. Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/145296/E93849.pdf. Accessed March 1, 2014. French.
63. Massip P, Cuzin L, Delpierre C, Garbay MF, Rousselle-Koch. oRchestra: une expérience pour améliorer la prise en charge globale des patients infectés par le VIH [oRchestra: an experience in order to improve the global care of HIV infected patients]. Med Mal Infect. 2003;33:117-121. French.
64. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121-131.
65. Tuldrà A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31 Suppl 3:S154-S157.
66. Haynes RB, McDonald H, Garg AX, Montague P. Intervention for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011.
67. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279-284.
68. Cacoub P, Ouzan D, Melin P, et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol. 2008;14:6195-6203.
69. Renou C, Lahmek P, Pariente A, et al. Impact of therapeutic education on the outcome of chronic hepatitis C treatment. Hepatology. 2009;729A (abstract).
70. Bernard-Leclerc J, Conort O, Bacq Y, Antier D. Impact d'un programme d'éducation thérapeutique sur les connaissances, l'observance et la satisfaction des patients traités pour hépatite chronique virale C [Impact of a therapeutic education program on the knowledge, the adherence and the satisfaction of the patients treated for viral chronic hepatitis C]. Ther Patient Educ. 2011;3:21-33.
71. Larrey D, Salsé A, Castelli C, et al. Groupe PEGOBS. Education thérapeutique systématique par une infirmière chez les patients atteints d'hépatite chronique C, traités par Interféron-Pégylé alpha2a - ribavirine (Protocole PEGOBS): impact sur la qualité de vie [Systematic therapeutic education by a nurse in patients with chronic hepatitis C, treated with pegylated interferon-alpha2a - ribavirin (PEGOBS Protocol): impact on quality of life]. Gastroenterol Clin Biol. 2009;33:63 (abstract CA-12). French.
72. Larrey D. Un exemple d'éducation thérapeutique par un infirmière sur l'observance et l'efficacité du traitement par bithérapie peginterferon-alpha2-ribavirine dans l'hépatite chronique C: protocole PEGOBS [An example of therapeutic education by a nurse on compliance and efficacy of treatment with bitherapy peginterferon-alpha2-ribavirin in chronic hepatitis C: PEGOBS protocol]. Bull Epidemiol Hebd. 2012;29-30:350-354. French.
73. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci. 2011;56:213-219.
74. Simon D, Traynard PY, Bourdillon F, Gagnayre R, Grimaldi A. Education Thérapeutique. Prévention et Maladies Chroniques [Therapeutic Education. Prevention and Chronic Diseases]. 2nd ed. Issy les Moulineaux: Elsevier Masson; 2009. French.
75. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. An Intern Med. 2012;156:817-833.
76. Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 2:S84-S95.
77. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804-811.
78. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
79. Jacobson IM, Gordon SC, Kowdley KV, et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877.
80. Chambon-Augoyard C, Faure S, Pageaux GP, Daurès JP, Larrey DG. Is there a risk to develop obesity and metabolic syndrome in patients with chronic hepatitis C after treatment-induced long term virological eradication? Hepatology. 2011;54:1619:1127A.